Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jul 15:13:15.
Print 2013.

Database of T cell-defined human tumor antigens: the 2013 update

Nathalie Vigneron  1 , Vincent Stroobant, Benoît J Van den Eynde, Pierre van der Bruggen
Affiliations
Review

Database of T cell-defined human tumor antigens: the 2013 update

Nathalie Vigneron et al. Cancer Immun. .

Abstract

The plethora of tumor antigens that have been--and are still being--defined required systematization to provide a comprehensive overview of those tumor antigens that are the most relevant targets for cancer immunotherapy approaches. Here, we provide a new update of a peptide database resource that we initiated many years ago. This database compiles all human antigenic peptides described in the literature that fulfill a set of strict criteria needed to ascertain their actual "tumor antigen" nature, as we aim at guiding scientists and clinicians searching for appropriate cancer vaccine candidates (www.cancerimmunity.org/peptide). In this review, we revisit those criteria in light of recent findings related to antigen processing. We also introduce the 29 new tumor antigens that were selected for this 2013 update. Two of the new peptides show unusual features, which will be briefly discussed. The database now comprises a total of 403 tumor antigenic peptides.

Keywords: CD4; CD8; HLA; T cell; database; peptide.

PubMed Disclaimer

References

    1. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognizedd by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643–1647. - PubMed
    1. van der Bruggen P, Stroobant V, Vigneron N, Van den Eynde B. Peptide database: T cell-defined tumor antigens. Cancer Immun. 2013 Accessed from: http://www.cancerimmunity.org/peptide/ - PMC - PubMed
    1. Vigneron N, Van den Eynde BJ. Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes. Cell Mol Life Sci. 2011;68:1503–1520. - PMC - PubMed
    1. Schultz ES, Lethé B, Cambiaso CL, Van Snick J, Chaux P, Corthals J, Heirman C, Thielemans K, Boon T, van der Bruggen P. A MAGEA3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res. 2000;60:6272–6275. - PubMed
    1. Vigneron N, Ooms A, Morel S, Ma W, Degiovanni G, Van den Eynde B. A peptide derived from melanocytic protein gp100 and presented by HLA-B35 is recognized by autologous cytolytic T lymphocytes on melanoma cells. Tissue Antigens. 2005;65:156–162. - PubMed

Publication types